Collectively, while most studies suggest a detrimental role of GSK3β activation in DKD, to conclusively define the role of GSK3β in DKD, it is necessary to employ DN models with kidney-specific GSK3β hyperactivity or KO, or to use highly selective and rigorous inhibitors. This evidence concerns the gene GSK3B and liver dysplastic nodule.